Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
April 28th, 2025

Company: Chordia Therapeutics Inc.
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: Head of Corporate Management Yoshihiko Satoh

Notice of Discontinuation of Development of CTX-177 (ONO-7018)

Kanagawa Japan

April 28th, 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; Chief Executive Officer: Hiroshi Miyake) ("Chordia") today announces that it has received the following notification from Ono Pharmaceutical Co., Ltd. ("Ono"), the licensee of CTX-177 (ONO-7018), an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1).

・Ono will discontinue development of CTX-177 (ONO-7018) for strategic reasons and return the rights to develop, manufacture and commercialize CTX-177 (ONO-7018) to Chordia.

In December 2020, Ono and Chordia entered into the license agreement granting Ono the exclusive worldwide rights to develop, manufacture and commercialize CTX-177 (ONO-7018) and related compounds. Ono is conducting Phase 1 clinical trials in the U.S. and Japan for patients with relapsed or refractory non-Hodgkin's lymphoma or chronic lymphocytic leukemia, but today Ono notified Chordia that it will discontinue development for strategic reasons.
Going forward, Chordia will have all rights of CTX-177 (ONO-7018) worldwide. Ono and Chordia will discuss the termination of the license agreement, including the management of ongoing studies, the transfer of data obtained to date, and the control of intellectual property, and Chordia will consider business options for the future.
No funds will be exchanged as a result of this matter. The license agreement defines the potential receipt of milestone payments based on the progress of development. Although the receipt of future milestone payments will not be expected as a result of this matter, Chordia does not expect any immediate impact on company's current R&D activities, including the progress of Phase 1/2 studies of the lead pipeline rogocekib. It will promptly announce any matters that should be disclosed in the future.

Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research of several clinical and preclinical assets, including MALT1 inhibitor CTX-177, CDK12 inhibitor CTX-439 and GCN2 inhibitors. For more information, please contact our website https://www.chordiatherapeutics.com/en/.